Skip to main content

Routine outpatient thyroid surgery cannot be recommended

Kasper Reinholdt Sørensen & Tejs Ehlers Klug,

1. feb. 2015
15 min.

Faktaboks

Fakta

More than 1,100 thyroid operations are performed at Danish ear-nose-throat departments annually, and the number is increasing [1]. Traditionally, thyroid surgery is performed as an inpatient procedure. In order to increase health-care productivity, some centres have experimented with outpatient thyroid surgery (OTS) [2, 3]. Initial studies show favourable patient acceptance and financial benefits compared with inpatient surgery [2].

Complications to thyroid surgery include recurrent laryngeal nerve injury, hypothyroidism, hypoparathyroidism, infection and haemorrhage. Post-thyroidectomy bleeding (PTB) (Figure 1) and hypocalcaemia are the complications that cause most concern when considering the safety of OTS. However, acute post-operative
hypocalcaemia is almost exclusively an issue after total thyroidectomy, which only comprised 19% (223/1,159) of thyroid surgery patients in 2013. Hence, the major obstacle for converting a significant number of thyroid surgeries into an outpatient regimen is PTB, which may cause compression of the trachea and compromise respiration [4].

The aims of the study were to examine the incidence of and risk factors for PTB in patients treated at our department. Furthermore, we aimed to explore the exact timespan from surgery to acknowledgement of haemorrhage. Finally, on the basis of our results and previous studies, we discussed whether OTS may be considered safe.

METHODS

The study was based on data reported prospectively by thyroid surgeons to the THYRKIR Database. Only patients treated at the Ear-Nose-Throat Department, Aarhus University Hospital, from January 2001 to August 2013, were included.

The patients were divided into two groups. Group I consisted of patients with PTB requiring surgical reoperation. Patients undergoing thyroid surgery who did not require reoperation for haemorrhage were included in Group II.

The following clinical and demographic data were available from the THYRKIR Database: age, gender, previous thyroid surgery, histology, extent of surgery, neck dissection, thyrotoxicosis, use of drainage, weight of gland, bleeding during surgery and intrathoracal involvement. The timespan from surgery to onset of haemorrhage was added in January 2005.

The medical records of patients in Group I were reviewed and additional data were obtained: amount of bleeding during re-operation, initial symptoms of haematoma, the use of anti-platelet or anti-coagulant medication, and the timespan from surgery to acknowledgement of haemorrhage.

Patients taking anti-platelet and anti-coagulant medication were advised to pause this medication at least three days prior to operation.

Statistical analyses were performed using the χ2- and the Fisher’s exact test to compare categorical variables. Student’s t-test and the Kruskal-Wallis test were used to compare continuous variables between the two groups. Multivariate logistic regression analysis was used on statistically significant risk factors for PTB found in the univariate analyses.

Trial registration: The study was approved by the Danish Data Protection Agency (1-16-02-170-14).

RESULTS

Incidence

During the study period, 1,404 patients underwent partial or complete thyroidectomy at our department. Among these, 108 patients underwent thyroid surgery twice. Thus, the total number of thyroid operations was 1,512. A total of 42 patients (2.8%) had PTB requiring surgical reoperation. Three patients experienced haemorrhage twice.

The number of thyroidectomies increased and the PTB rate decreased significantly during the study period from an annual average of 78 operations in the 2001-2008 period and a PTB rate of 3.9% (24/624) to 178 annual surgeries and a PTB rate of 2.0% (18/888) in the 2009-August 2013 period (p = 0.034, χ2). The median hospitalisation time was three days (range: 2-16 days) for patients with haemorrhage, and two days (range: 1-90 days) for patients without haemorrhage (p < 0.001, Kruskal-Wallis).

Risk factors

The clinical characteristics of patients with and without PTB are shown in Table 1.

In univariate analyses, male gender (odds ratio (OR) = 1.85, 95% confidence interval (CI): 1.00-3.28), thyrotoxicosis (OR = 2.68, 95% CI: 1.24-5.83) and the use of drainage (OR = 4.45, 95% CI: 1.12-38.44) were found to be statistically significantly associated with a higher frequency of haemorrhage. Using multivariate logistic regression analysis on these three variables, male gender and thyrotoxicosis remained significantly associated with an increased risk of haemorrhage (p = 0.019 and
p = 0.021, respectively), while the use of drainage was insignificant (p = 0.067).

Bilateral procedures and a higher weight of the excised gland tended to be more common among patients with haemorrhage, but did not reach statistical significance (p = 0.082 and p = 0.073, χ2 and Kruskal-Wallis,
respectively).

Onset of symptoms

Table 2 shows the clinical characteristics of the patients with PTB. The median timespan from surgery to onset of symptoms of haemorrhage was 2 h (range: < 1-96 h). The majority of patients presented with symptoms within the first 6 h (63%), whereas 25% and 13% of patients developed haematoma 6 to 24 h and more than 24 h after surgery, respectively. The median blood loss during reoperation was 300 ml (range: 15-2,000 ml) (only registered in twelve patients).

No statistically significant differences in clinical characteristics were found between the patients with PTB who were recognised less than 6 h after surgery and those in whom haemorrhage occurred more than 6 h
after surgery.

Biochemical coagulation data were abnormal in 18% (7/40) of patients with PTB. A total of eight (19%) patients with PTB took anti-platelet medication daily. Six of these patients had paused their anti-platelet medication 3-7 days prior to surgery, while two patients had not paused this medication despite receiving instruction to do so.

Two (5%) patients with PTB had paused their anti-coagulant medication (warfarin) 4 and 5 days prior to surgery and both patients were given low molecular weight heparin until the night before surgery. One of these patients had a haemorrhage 92 h after surgery.

In the vast majority of cases, the first signs of PTB were neck swelling and/or haemorrhage from the cicatrice (Table 2). One patient required urgent reoperation due to haematoma-induced respiratory failure. No patients died from complications to thyroid surgery during the study period.

DISCUSSION

Incidence of post-thyroidectomy bleeding

The incidence of PTB varies greatly between studies (0.03-4.2%) (Table 3) [1-13]. However, most studies find incidence rates below 2%, and our PTB of 2.8% seems relatively high. Godballe et al [1] found an overall haemorrhage frequency of 4.2% in a national Danish study, with a wide variation between individual departments. In the present study, the frequency of haemorrhage may have been influenced by the fact that patients with thyrotoxicosis, malignancy, intrathoracal involvement, extensive surgery and previous thyroid surgery are relatively frequent at our department. The PTB rate decreased significantly (from 3.9% to 2.0%) as the number of surgeries rose over time.

Risk factors for post-thyroidectomy bleeding

A multivariate analysis identified two statistically significant risk factors for PTB: male gender and thyrotoxicosis. Previous studies have also found male gender and thyrotoxicosis to be associated with an increased risk of PTB [1, 4, 6, 13]. In the univariate analysis, the use of drainage was significantly associated with an increased risk of haemorrhage. Most likely, drainage was used more often in patients with large or thyrotoxic glands, and drainage is a quasi-variable for other factors associated with increased risk of haemorrhage and not a real risk factor. A Cochrane meta-analysis found no significant influence of the use of drainage on the frequency of PTB [14].

Previous studies have identified other risk factors for PTB including higher age [1, 6], malignant histology [1], bilateral surgery [1,4], extent of resection (total or near-total thyroidectomy) [4], previous thyroid surgery [4, 5] and size of dominant nodule [5]. However, in other large studies no risk factors for PTB were found [7, 9, 12, 15]. Although an increased risk of haemorrhage after surgery in other organs has been found in patients taking anti-coagulant medication [16], previous studies on thyroid surgery have not identified any such association [9, 12].

Onset of symptoms

We found that the majority (63%) of haemorrhages requiring reoperation occurred within 6 h after surgery, which is similar to the findings in most other studies (Table 3) [4, 5, 9, 10, 12]. However, some studies found that a considerable proportion (18-90%) of patients had onset of symptoms of haematoma development later than 6 h after surgery [1, 2, 4, 5, 9-12, 15, 17]. The key question when considering OTS is if patients with haemorrhage occurring more than 6 h after surgery experience acute respiratory failure and thus require urgent reoperation. In the present study, only one patient was identified with acute respiratory distress (2 h after surgery). However, it is possible that more patients required urgent reoperation as this information was not clearly described in all medical records.

Burkey et al found that 50% of patients with haemorrhage after thyroid or parathyroid surgery presented with respiratory distress [9]. The timespan from surgery to onset of symptoms ranged from less than 1 h to 16 h. Dixon et al [11] reported two patients with PTB requiring urgent reoperation, both within a few hours after surgery. Promberger et al [4] found that 1.7% (9/519) of patients with PTB required urgent intervention due to acute respiratory problems. The median timespan from skin closure to onset of symptoms was significantly longer in these patients with acute respiratory failure than in other patients with PTB (330 versus 100 minutes, respectively).

Three of these nine patients died from respiratory failure (overall thyroidectomy mortality rate: 0.01% (3/30,142)). Schwartz et al [16] calculated that for every 100,000 thyroidectomies performed, 94 deaths secondary to post-operative bleeding could potentially be prevented by a 24-h hospitalisation compared with a 6-h observation.

Limitations

Our study carries several limitations. Some potential risk factors (anti-platelet and anti-coagulation medication, coagulation status) for PTB were not included in the THYRKIR Database and, due to the number of patients, they were only retrieved from the medical records of patients with PTB. Hence, no statistical calculations concerning these factors could be made and the relevance of these factors is largely uncertain. Moreover, the dataset in the THYRKIR Database was incomplete (for instance the use of anti-thyroid medication was only registered for 58% of the patients), which may bias our results on risk factors.

The number of patients with PTB is relatively low, especially when sub-stratifying into three categories on the basis of timespan from surgery to acknowledgement of haemorrhage. Thus, our recommendations concerning the safety of outpatient thyroid surgery are primarily based on previous studies and to a much lesser extent on our findings in the present study.

Outpatient thyroidectomy

Hospitalisation for 24 h after thyroidectomy is recommended by most previous researchers [3, 4, 18]. Although some PTB present more than 24 h after surgery, no studies report cases with urgent reoperation for haematoma later than 16 h post-operatively [9]. Thus, late onset PTB seems to be safely managed subacutely. Infrequently, acute reoperation due to respiratory failure is required later than 6 h after surgery. Hence, we find that routine OTS cannot be recommended. However, it remains unexplored if patients requiring urgent reoperation have significant risk factors associated with PTB and if careful selection of low-risk patients is feasible.

Several authors report that OTS is safe in selected patients (Table 3) [2, 7, 10, 11, 19]. Rosenbaum et al [10] found that unilateral surgery was safely performed as OTS with discharge only 4 h post-operatively. Snyder et al [2] selected patients for OTS on the basis of co-morbidities and anticipated less extensive surgery. However, in the only prospective study performed, Godballe et al [1] did not recommend OTS due to the risk of late PTB.

The American Thyroid Association (ATA) has recently published a meta-analysis and consensus statement on the eligibility criteria for OTS [20]. They concluded that a variety of comorbidities (among others uncompensated cardiac or respiratory disease, dialysis-dependent renal failure, anti-coagulant or anti-platelet therapy, etc.) may be considered relative contraindications to OTS. The ATA also advises that inpatient care
after thyroidectomy is favoured by social factors such as communication and language barriers, challenges in transportation and lack of family/friend support.

Thus, at present, it seems difficult to prepare precise guidelines for the selection of patients suitable for OTS based on scientifically supported criteria. However, both factors associated with an increased risk of PTB (male gender and thyrotoxicosis) as well as social factors are important to take into consideration.

CONCLUSION

In light of the fact that PTB infrequently develops more than 6 h after surgery (some with fatal outcome) and as risk factors associated with severe, sudden and late onset PTA are not well-described, routine OTS cannot be recommended. Selection criteria for OTS have previously been suggested, but additional research is warranted. As PTB requiring urgent reoperation can develop up to 16 h post-operatively, we recommend that patients undergoing thyroid surgery be observed for at least 16 h or, as a minimum, for 6 h followed by a stay at a nearby hospital hotel until clinical examination and discharge 16 to 24 h after surgery.

Correspondence: Kasper Reinholdt Sørensen, Øre-næse-hals-afdeling H, Hoved-Neuro-Centret, Aarhus Universitetshospital, Bygn. 10, Nørrebrogade 44, 8000 Aarhus C, Denmark. E-mail: kasperrs@gmail.com

Accepted: 15 December 2014

Conflicts of interest:Disclosure forms provided by the authors are available with the full text of this article at www.danmedj.dk

Referencer

REFERENCES

  1. Godballe C, Madsen AR, Pedersen HB et al. Post-thyroidectomy hemorrhage: a national study of patients treated at the Danish Departments of ENT Head and Neck Surgery. Eur Arch Otorhinolaryngol 2009;266:1945-52.

  2. Snyder SK, Hamid KS, Roberson CR et al. Outpatient thyroidectomy is safe and reasonable: Experience with more than 1,000 planned outpatient procedures. J Am Coll Surg 2010;210:575-84.

  3. Materazzi G, Dionigi G, Berti P et al. One-day thyroid surgery: retrospective analysis of safety and patient satisfaction on a consecutive series of 1,571 cases over a three-year period. Eur Surg Res 2007;39:
    182-8.

  4. Promberger R, Ott J, Kober F et al. Risk factors for postoperative bleeding after thyroid surgery. Br J Surg 2012;99:373-9.

  5. Lang BH, Yih P, Lo CY. A review of risk factors and timing for postoperative hematoma after thyroidectomy: is outpatient thyroidectomy really safe? World J Surg 2012;36:2497-2502.

  6. Bergenfelz A, Jansson S, Kristoffersson A et al. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch Surg 2008;393:667–73.

  7. Stack BC, Moore E, Spencer H et al. Outpatient thyroid surgery data from the University Health System (UHC) Consortium. Otolaryngol Head Neck Surg 2013;148:740-5.

  8. Rosato L, Avenia N, Bernante P et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 2004 28;271-6.

  9. Burkey SH, van Heerden JA, Thompson GB et al. Reexploration for symptomatic hematomas after cervical exploration. Surgery 2001;130:
    914-20.

  10. Rosenbaum MA, Haridas M, McHenry CR. Life-threatening neck hematoma complicating thyroid and parathyroid surgery. Am J Surg 2008;
    195:339-43.

  11. Dixon J, Snyder SK, Lairmore TC et al. A novel method for the management of post-thyroidectomy or parathyroidectomy hematoma: a single-institution experience after over 4,000 central neck operations. World J Surg 2014;38:1262-7.

  12. Leyre P, Desurmont T, Lacoste L et al. Does the risk of compressive hematoma after thyroidectomy authorize 1-day surgery? Langenbecks Arch Surg 2008;393:733-7.

  13. Palestini N, Tulletti V, Cestino L et al. Post-thyroidectomy cervical haematoma. Minerva Chir 2005;60:37-46

  14. Samraj K, Gurusamy KS. Wound drains following thyroid surgery Cochrane Database Syst Rev 2007;4:CD006099.

  15. Abbas G, Dubner S, Heller KS. Re-operation for bleeding after thyroidectomy and parathyroidectomy. Head Neck 2001;23:544-6.

  16. Schwartz AE, Clark OH, Ituarte P et al. Therapeutic controversy: thyroid surgery – the choice. J Clin Endocrinol Metab 1998;83:1097-105.

  17. Lee HS, Lee BJ, Kim SW et al. Patterns of post-thyroidectomy hemorrhage. Clin Exp Otorhinolaryngol 2009;2:72-7.

  18. Shaha AR, Jaffe BM. Practical management of post-thyroidectomy hematoma. J Surg Oncol 1994;57:235-8.

  19. Seybt M, Terris DJ. Outpatient thyroidectomy – experience in over 200 patients. Laryngoscope 2010;120:959-63.

  20. Terris DJ, Snyder S, Carneiro-Pla D et al. American Thyroid Association statement on outpatient thyroidectomy. Thyroid 2013;23:1193-202.